Ponatinib (Iclusig) 45mg Tablets | BCR-ABL T315I Inhibitor | GLT

What is Iclusig (Ponatinib)?

Iclusig (ponatinib) is a third-generation BCR-ABL tyrosine kinase inhibitor (TKI) developed by ARIAD Pharmaceuticals and now marketed by Takeda. It is the only approved TKI that maintains activity against the T315I gatekeeper mutation of BCR-ABL, a mutation that confers resistance to all first- and second-generation TKIs.

What is Iclusig Used For?

Iclusig is FDA-approved for the treatment of adult patients with chronic-phase, accelerated-phase, or blast-phase chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other TKI therapy is indicated. It is specifically indicated for patients with resistance or intolerance to at least two prior TKIs, and for T315I-positive CML or Ph+ ALL.

How Does Ponatinib Work?

Ponatinib binds to the ATP-binding site of the BCR-ABL kinase domain and inhibits its activity. Unlike earlier TKIs, ponatinib was designed to fit into the sterically hindered binding pocket created by the T315I mutation, allowing it to overcome this resistance mechanism. It also inhibits other kinases including VEGFR, PDGFR, FGFR, KIT, RET, and FLT3.

FDA-Approved Indications

• Chronic-phase CML with resistance or intolerance to at least two prior TKIs
• Accelerated-phase or blast-phase CML for whom no other TKI is indicated
• Ph+ ALL for whom no other TKI is indicated
• T315I-positive CML (chronic, accelerated, or blast phase)
• T315I-positive Ph+ ALL

Limitation of use: Iclusig is not indicated for newly diagnosed chronic-phase CML.

Dosage & Administration

The recommended starting dose is 45 mg once daily, taken orally with or without food. In chronic-phase CML, the dose is reduced to 15 mg once daily upon achievement of ≤1% BCR-ABL1 (IS). In newly diagnosed Ph+ ALL in combination with chemotherapy, the starting dose is 30 mg once daily, reduced to 15 mg upon achievement of MRD-negative complete remission. Dose must be determined and adjusted by the treating oncologist.

Common Side Effects

The most common adverse reactions (≥20%) include rash, arthralgia, abdominal pain, headache, constipation, dry skin, hypertension, fatigue, fluid retention, pyrexia, nausea, and myelosuppression (thrombocytopenia, neutropenia, anemia).

Important Safety Information

Iclusig carries a boxed warning for arterial occlusive events, venous thromboembolic events, heart failure, and hepatotoxicity. These serious events, including fatalities, have occurred in patients with and without pre-existing cardiovascular risk factors. Regular cardiovascular and liver function monitoring is required.

Storage

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Keep in the original container and protect from light.

Why Choose the GLT?

GIVE LIFE TIME LIMITED supplies authentic Iclusig sourced through licensed channels with full batch traceability. Key advantages include:

• Authentic original-brand product from Takeda
• Full documentation including Certificate of Analysis and export paperwork
• Global export with reliable international logistics
• Dedicated support from inquiry to delivery

Quality Assurance

All Iclusig supplied by GIVE LIFE TIME LIMITED is sourced through authorized channels with full batch traceability and Certificate of Analysis (COA). Every shipment includes export-ready documentation: commercial invoice, packing list, and Certificate of Origin.

How to Order

To request pricing and place an order, please follow these steps:

1. Send your prescription or case file via WhatsApp or email — reviewed within 24 hours
2. Receive a formal quotation with pricing, availability, and shipping options
3. Confirm and arrange payment via bank transfer or PayPal
4. Ship globally with full export documentation and tracking

Send your prescription / case file now: WhatsApp: +86 15234153837

Frequently Asked Questions

Is Iclusig the only drug for the T315I mutation?

Iclusig is the only approved TKI that maintains activity against the T315I gatekeeper mutation of BCR-ABL, which confers resistance to all first- and second-generation TKIs.

Is a prescription required?

Yes. Iclusig is a prescription-only medicine. A valid prescription from a licensed oncologist is required.

How long does international shipping take?

Most orders are dispatched within 3-5 business days after payment confirmation, with delivery times of 7-14 business days depending on destination.

What monitoring is required during treatment?

Regular cardiovascular, liver function, and blood count monitoring is required. Patients should follow their oncologist's monitoring schedule closely.